FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2238647672> ?p ?o ?g. }

• W2238647672 endingPage "30" @default.
• W2238647672 startingPage "111" @default.
• W2238647672 abstract "Osteoporosis is still an important health problem in modern societies. The densitometric criterion for the diagnosis of this condition established by WHO in 1994 is bone mass density (BMD) lower than 2.5 standard deviation (SD) from the mean value for young healthy individuals of the same sex. Between 60 and 90% of bone density (quantity of bone tissue in the human skeleton) at the time when growth is terminated is genetically determined. For this reason, genes predisposing to osteoporosis and mechanisms of their activity remain the object of investigations. Among them are genes coding for vitamin D receptor (VDR), estrogen receptor (ER), type I collagen, TGF-beta and IL-6. Diminishing bone density past the age of thirty is a physiologic process. Bone loss averages 0.3-0.6% per year. Acceleration of this process to 1.2-6% per year in postmenopausal women has been attributed to constantly decreasing estrogen concentration. Hence, the gold standard in osteoporosis prevention and treatment includes estrogen-progestagen therapy enriched with vitamin D analogues, calcium-rich diet and regular physical exercises. Treatment of osteoporosis can be long and expensive. The condition may lead to disability. Osteoporotic fractures and their complications may be fatal. For these reasons, the chief priority in osteoporosis is prevention. Unfortunately, current diagnostic methods (for detection of osteoporosis and monitoring of treatment) remain unsatisfactory. Molecular techniques offer a promising approach to diagnosis and monitoring of therapy. Additionally, the risk of osteoporosis in 1st degree relatives can be assessed and early prevention can be started. The present study addressed the following questions: 1. Are there differences in spine BMD in untreated women with postmenopausal osteoporosis depending on polymorphism of VDR and ER genes? 2. Does efficacy of treatment (increase in spine BMD) in women with postmenopausal osteoporosis depend on polymorphism of VDR and ER genes? 3. What estrogen concentration is necessary to protect bone tissue depending on the polymorphism of VDR and ER genes? The study group included 44 postmenopausal women aged 44-75 years with primary osteoporosis on cyclic HRT (hormonal replacement therapy). Two hormonal preparations were administered: Systen 50 (Jansen Cilag) transdermal system twice per week between day 1 and 21 of the cycle; Provera (Upjohn) 5 mg tablets daily between day 16 and 27 of the cycle. This therapy was supplemented with vitamin D analogue (Alphacalcidolum, Glaxo-Poznan) orally at 0.25 microg per day, calcium-enriched (1200 mg daily) diet and regular physical exercise. Patients were qualified to the study on the basis of a questionnaire. Women with secondary osteoporosis were excluded. TSH, FT3, and FT4 concentrations, as well as fasting glucose were measured. 24 h glycemia was established in women with elevated glucose levels. Polymorphism of the ER gene was studied with Xba I and Pvu II restrictases. Polymorphism of the VDR gene was studied with Bsm I restrictase. Age and BMI were recorded. Spine BMD was determined with DEXA (Dual Energy X-ray Absorptiometry (Lunar instrument) before treatment and after 12 months of HRT. Serum estradiol concentrations were measured before treatment and after 2 months of HTR. The following conclusions were drawn: 1. There is no connection between VDR and ER gene polymorphism and degree of osteoporosis before treatment. 2. XX, PP and Bb markers or X, P, B alleles are associated with a significant decrease in therapeutic efficacy. Nevertheless, satisfactory results were achieved in each woman with primary osteoporosis. 3. Estradiol concentration in serum before and during HRT does not depend on the polymorphism of VDR and ER genes." @default.
• W2238647672 created "2016-06-24" @default.
• W2238647672 creator A5074828619 @default.
• W2238647672 date "2003-01-01" @default.
• W2238647672 modified "2023-09-23" @default.
• W2238647672 title "[The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes]." @default.
• W2238647672 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15552843" @default.
• W2238647672 hasPublicationYear "2003" @default.
• W2238647672 type Work @default.
• W2238647672 sameAs 2238647672 @default.
• W2238647672 citedByCount "2" @default.
• W2238647672 crossrefType "journal-article" @default.
• W2238647672 hasAuthorship W2238647672A5074828619 @default.
• W2238647672 hasConcept C121608353 @default.
• W2238647672 hasConcept C124490489 @default.
• W2238647672 hasConcept C126322002 @default.
• W2238647672 hasConcept C134018914 @default.
• W2238647672 hasConcept C170033053 @default.
• W2238647672 hasConcept C179639408 @default.
• W2238647672 hasConcept C2776541429 @default.
• W2238647672 hasConcept C2776886416 @default.
• W2238647672 hasConcept C2777164284 @default.
• W2238647672 hasConcept C2777944059 @default.
• W2238647672 hasConcept C2779329777 @default.
• W2238647672 hasConcept C2780712178 @default.
• W2238647672 hasConcept C42407357 @default.
• W2238647672 hasConcept C530470458 @default.
• W2238647672 hasConcept C71924100 @default.
• W2238647672 hasConcept C84606932 @default.
• W2238647672 hasConceptScore W2238647672C121608353 @default.
• W2238647672 hasConceptScore W2238647672C124490489 @default.
• W2238647672 hasConceptScore W2238647672C126322002 @default.
• W2238647672 hasConceptScore W2238647672C134018914 @default.
• W2238647672 hasConceptScore W2238647672C170033053 @default.
• W2238647672 hasConceptScore W2238647672C179639408 @default.
• W2238647672 hasConceptScore W2238647672C2776541429 @default.
• W2238647672 hasConceptScore W2238647672C2776886416 @default.
• W2238647672 hasConceptScore W2238647672C2777164284 @default.
• W2238647672 hasConceptScore W2238647672C2777944059 @default.
• W2238647672 hasConceptScore W2238647672C2779329777 @default.
• W2238647672 hasConceptScore W2238647672C2780712178 @default.
• W2238647672 hasConceptScore W2238647672C42407357 @default.
• W2238647672 hasConceptScore W2238647672C530470458 @default.
• W2238647672 hasConceptScore W2238647672C71924100 @default.
• W2238647672 hasConceptScore W2238647672C84606932 @default.
• W2238647672 hasLocation W22386476721 @default.
• W2238647672 hasOpenAccess W2238647672 @default.
• W2238647672 hasPrimaryLocation W22386476721 @default.
• W2238647672 hasRelatedWork W1976732767 @default.
• W2238647672 hasRelatedWork W1994898168 @default.
• W2238647672 hasRelatedWork W2002141434 @default.
• W2238647672 hasRelatedWork W2015993219 @default.
• W2238647672 hasRelatedWork W2031926698 @default.
• W2238647672 hasRelatedWork W2039678305 @default.
• W2238647672 hasRelatedWork W2041135386 @default.
• W2238647672 hasRelatedWork W2053792931 @default.
• W2238647672 hasRelatedWork W2063811090 @default.
• W2238647672 hasRelatedWork W2082134981 @default.
• W2238647672 hasRelatedWork W2091803762 @default.
• W2238647672 hasRelatedWork W2128880903 @default.
• W2238647672 hasRelatedWork W2300868068 @default.
• W2238647672 hasRelatedWork W2409525496 @default.
• W2238647672 hasRelatedWork W2414207092 @default.
• W2238647672 hasRelatedWork W2419011950 @default.
• W2238647672 hasRelatedWork W2424735838 @default.
• W2238647672 hasRelatedWork W2505042347 @default.
• W2238647672 hasRelatedWork W2970145395 @default.
• W2238647672 hasRelatedWork W842955364 @default.
• W2238647672 hasVolume "49" @default.
• W2238647672 isParatext "false" @default.
• W2238647672 isRetracted "false" @default.
• W2238647672 magId "2238647672" @default.
• W2238647672 workType "article" @default.